Zhi Tong Cai Jing·2026-02-03 02:38Core Viewpoint - WuXi Biologics (02269) has signed a licensing and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T cell engager (TCE) aimed at treating B cell-mediated autoimmune diseases, which has positively impacted its stock price [1] Group 1: Company Developments - WuXi Biologics' stock rose over 4%, currently trading at 37.04 HKD with a transaction volume of 439 million HKD [1] - The agreement allows Vertex to obtain global exclusive development and commercialization rights for the trispecific TCE, which is in the preclinical stage [1] - WuXi Biologics will receive an upfront payment and is eligible for milestone payments related to development, registration, and sales, as well as royalties from product sales [1] Group 2: Industry Implications - The collaboration focuses on a novel therapeutic approach for B cell-mediated autoimmune diseases, indicating a growing interest in innovative treatments within the biopharmaceutical industry [1] - The partnership highlights the trend of biopharmaceutical companies seeking external expertise for drug development, which may lead to increased collaboration opportunities in the sector [1]